Vyvanse FAERS Safety Signals: What the Post-Market Data Actually Shows

What Is FAERS and Why Does It Matter for Vyvanse?

FDA's Adverse Event Reporting System (FAERS) is the agency's primary post-market pharmacovigilance database. Reports flow in from patients, prescribers, and manufacturers. No causal relationship is confirmed until regulatory review, but signal detection algorithms like the Empirical Bayes Geometric Mean (EBGM) and the Reporting Odds Ratio (ROR) help identify which drug-event pairs appear more often than chance alone would predict.

For a Schedule II stimulant with tens of millions of annual U.S. Prescriptions, FAERS data carry outsized clinical weight. Vyvanse differs from mixed amphetamine salts because it is a prodrug: the lysine moiety must be cleaved in the gut to release d-amphetamine, which theoretically blunts the sharp plasma spike associated with intranasal or intravenous misuse. That pharmacokinetic rationale was part of Takeda's original NDA argument.

How FAERS Reports Are Generated

Reports enter FAERS as MedDRA-coded preferred terms. For Vyvanse, the suspect drug can be coded as "lisdexamfetamine" or the brand name. Duplicate de-identification is imperfect, so published disproportionality analyses typically apply deduplication rules before calculating signal metrics. A reporting odds ratio above 2.0 with a lower 95% confidence interval above 1.0 is a conventional threshold for a "detected signal," though thresholds vary by research group.

FAERS Data Are Not Incidence Rates

A critical point: FAERS tallies reports, not rates. A drug with 17 million annual prescriptions will accumulate more raw reports than a drug with 500,000 prescriptions even if the underlying event rate is identical. Disproportionality statistics partially correct for this, but under-reporting, stimulated reporting after media coverage, and confounding by indication all limit interpretation. The FDA's Sentinel Initiative was designed specifically to complement FAERS with denominator data from insurance claims.

The Vyvanse FDA Label: A Roadmap for the Highest-Priority Signals

The current Prescribing Information for Vyvanse (NDA 021977) consolidates decades of clinical and post-market data into actionable risk language. The full label is available through Drugs@FDA.

Black-Box Warning: Abuse and Dependence

The boxed warning states that amphetamines have a "high potential for abuse and dependence." Prolonged use may lead to "frank psychotic episodes," particularly at supratherapeutic doses. The label explicitly instructs prescribers to assess abuse risk before prescribing and to monitor patients for "signs of abuse and dependence" throughout treatment.

This language is not boilerplate. FAERS contains thousands of reports coded under MedDRA terms including "drug dependence," "drug abuse," "intentional product misuse," and "substance-induced psychosis" with lisdexamfetamine as the primary suspect. A 2020 disproportionality analysis published in Pharmacoepidemiology and Drug Safety found that stimulants as a class generated strong abuse-related signals, and lisdexamfetamine's ROR for "drug dependence" remained elevated even after adjusting for ADHD indication.

Cardiovascular Warnings

Section 5.2 of the Vyvanse label covers serious cardiovascular events. The label warns of "sudden death in patients who have pre-existing structural cardiac abnormalities or other serious heart problems." Mean increases in blood pressure of approximately 2 to 4 mmHg systolic and 1 to 2 mmHg diastolic were observed in controlled trials, with larger increases in individual patients.

FAERS reports corroborate this. A query of publicly accessible FAERS data for lisdexamfetamine returns thousands of case reports coded under "palpitations," "tachycardia," "hypertension," and "cardiovascular disorder." The label therefore mandates avoiding Vyvanse in patients with structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, and coronary artery disease.

Psychiatric Adverse Events

New-onset psychosis or mania can occur even in patients without prior psychiatric history. The label cites controlled trial data showing that approximately 0.1% of patients experienced treatment-emergent psychotic events. Post-market FAERS reports extend this picture: "hallucination," "aggression," "mania," and "anxiety" appear repeatedly as preferred terms with lisdexamfetamine listed as the primary or suspect drug.

Cardiovascular Safety Signals in Depth

Cardiovascular adverse events represent one of the three dominant FAERS signal clusters for Vyvanse. The FDA's 2006 pediatric cardiovascular meta-analysis, commissioned before Vyvanse's approval, found no statistically significant increase in serious cardiovascular events compared to placebo across mixed amphetamine data, but absolute event rates were low and follow-up was short.

Tachycardia and Hypertension

In the key adult ADHD trial supporting the initial NDA, mean pulse increased by 3.5 beats per minute versus placebo. Small on average, but clinically meaningful in patients with baseline tachycardia or hypertension. FAERS reports tagged "tachycardia" for lisdexamfetamine numbered in the thousands as of 2023, making it one of the top 10 reported preferred terms for the drug.

The American Heart Association's 2008 scientific statement on ADHD medications recommended that "all children and adolescents" receiving stimulants have a cardiology referral if personal or family history of cardiac disease exists. That guidance remains relevant today.

Long-Term Cardiovascular Risk

A Sentinel-linked cohort study published in JAMA Psychiatry in 2019 tracked more than 200,000 new stimulant users and found no significant increase in acute myocardial infarction or stroke at 365 days compared to matched non-users. View that analysis via PubMed. The study duration was still too short to rule out longer-term effects, and Sentinel continues active surveillance on this question.

Sudden Death: What the Label Means Clinically

The label's mention of sudden death in patients with structural cardiac abnormalities comes from spontaneous reports and case series, not from controlled trials where such patients were excluded by design. FAERS sudden death reports involving lisdexamfetamine are few in absolute number but receive high regulatory priority because of their severity. An EBGM signal does not mean your patient will experience sudden death; it means the drug-event pair is reported more than background rates predict and warrants clinical vigilance.

Psychiatric and Neurological Safety Signals

Psychiatric signals are the second dominant cluster in FAERS for Vyvanse, and in some disproportionality analyses they generate stronger statistical signals than the cardiovascular cluster.

Psychosis and Mania

The Vyvanse label cites case reports of "treatment-emergent psychotic or manic symptoms" in patients with no prior history at recommended doses. The mechanism is straightforward: d-amphetamine increases synaptic dopamine and norepinephrine via reuptake inhibition and reverse transport. High dopaminergic tone in the mesolimbic pathway can trigger psychotomimetic effects, particularly in individuals with latent vulnerability.

FAERS reports coded under "psychotic disorder," "hallucination," and "mania" for lisdexamfetamine carry a disproportionality signal that persists across multiple published analyses. Clinicians should ask directly about first-degree family history of bipolar disorder and schizophrenia before starting treatment.

Anxiety, Insomnia, and Emotional Lability

These three symptoms appear consistently in both controlled trial adverse event tables and FAERS preferred-term listings. In the key BED (binge eating disorder) trial of lisdexamfetamine 50 mg and 70 mg (N=390), anxiety occurred in 9.6% of the treatment group versus 2.9% placebo, and insomnia in 19.5% versus 5.8% placebo. That data is accessible via the FDA's drug label archive. Insomnia and anxiety also rank among the top five most frequently reported FAERS preferred terms for the drug in most recent calendar-year extracts.

Suicidality

The label does not carry a specific suicidality warning, unlike some other CNS medications. However, FAERS contains reports of suicidal ideation and completed suicide with lisdexamfetamine. Establishing directionality is particularly difficult here because untreated ADHD itself is associated with elevated suicide risk. A 2014 study in JAMA Internal Medicine (N=37,936) found that ADHD pharmacotherapy was associated with a reduced risk of suicide attempts during treated versus untreated periods. PubMed link. The FAERS signal does not override that epidemiological context.

Abuse, Misuse, and Dependence Signals

This category deserves its own section given the black-box warning. The prodrug design was intended to reduce abuse liability. Early pharmacokinetic studies showed that intranasal and intravenous administration of lisdexamfetamine produced smaller Cmax values than equivalent d-amphetamine doses, reducing the rapid plasma spike associated with euphoria and reinforcement.

Real-World Abuse Reports Despite Prodrug Design

Despite the pharmacokinetic rationale, FAERS contains substantial abuse and misuse reports. A 2017 study by Wigal et al. In the Journal of Attention Disorders used a retrospective design to examine real-world safety data across stimulant formulations. Wigal et al., J Atten Disord 2017 (PubMed 26861148) found that clinical and post-market tolerability profiles for lisdexamfetamine aligned broadly with other extended-release amphetamine formulations, though direct abuse-report comparisons between formulations carry significant methodological caveats.

The Drug Enforcement Administration's ARCOS database and the FDA's Drug Abuse Warning Network (DAWN) data both document lisdexamfetamine-related emergency department visits and treatment admissions, though these figures remain lower on a per-prescription basis than immediate-release amphetamine salts.

Diversion and Non-Medical Use

College-age populations drive a disproportionate share of non-medical stimulant use. Survey data from the National Survey on Drug Use and Health (NSDUH) estimated that approximately 3.8 million Americans aged 12 and older misused prescription stimulants in 2021. CDC summary statistics. Lisdexamfetamine's market share of the prescription stimulant category means it accounts for a meaningful fraction of that figure, even if per-prescription misuse rates are lower than for immediate-release products.

Gastrointestinal and Other Signals

GI adverse events are the third prominent FAERS cluster for Vyvanse. Decreased appetite, nausea, dry mouth, and constipation were reported in 30% to 39% of patients in the key ADHD and BED trials. These numbers reflect trial populations; FAERS reports for "decreased appetite," "weight loss," and "nausea" are correspondingly high.

Weight Loss as a Safety Concern

Vyvanse is not approved for weight loss. The label carries a specific warning about weight loss in pediatric patients and calls for height and weight monitoring at all follow-up visits. In the 4-week pediatric ADHD trial, patients lost an average of 1.2 lb versus a 2.0-lb gain in the placebo group. Over longer treatment durations, this discrepancy compounds. FAERS reports under "decreased appetite" and "weight decreased" for children on lisdexamfetamine number in the hundreds annually.

Raynaud's Phenomenon

A less publicized signal: FAERS and published case reports describe peripheral vasospasm consistent with Raynaud's phenomenon in patients taking amphetamines including lisdexamfetamine. The label acknowledges peripheral vasculopathy under Section 5.5. This signal is not high-volume in absolute terms, but the association between sympathomimetic agents and Raynaud's has biological plausibility via alpha-1 adrenergic vasoconstriction.

The FDA Sentinel Initiative and Lisdexamfetamine

The Sentinel System differs fundamentally from FAERS. Rather than collecting spontaneous reports, Sentinel queries electronic health record and insurance claims data from over 100 million covered lives. For Vyvanse, Sentinel has been used to examine cardiovascular outcomes in new users versus matched controls across multiple surveillance cycles.

The HealthRX Regulatory Team uses the following three-tier framework when evaluating any Schedule II stimulant's post-market safety profile:

Tier 1 (Label-supported signals): Events already reflected in boxed warnings or contraindications. For Vyvanse, this includes cardiovascular sudden death in structural heart disease, new-onset psychosis, and drug dependence. These require active clinical management, not further investigation.

Tier 2 (Emerging signals under Sentinel review): Events with statistically elevated ROR in FAERS but not yet incorporated into the label. For lisdexamfetamine, peripheral vasospasm and serotonergic interactions (particularly with concurrent SSRI use) fall here.

Tier 3 (Hypothesis-generating FAERS noise): Low-volume reports without biological plausibility or consistent disproportionality. These warrant documentation but not prescribing changes.

This tiered approach allows clinicians to separate actionable safety information from background signal noise without dismissing either source of evidence.

Key Label Updates and Regulatory History

Vyvanse received its first FDA approval on June 23, 2007, for ADHD in patients aged 6 to 12. The indication was extended to adolescents and adults over subsequent years. The BED approval came in January 2015, making Vyvanse the first FDA-approved pharmacotherapy for that condition.

The label has undergone multiple revisions since 2007. Notable post-market additions include:

• Expanded cardiovascular language specifying pre-existing conditions associated with sudden death risk (added 2008 revision cycle).
• Peripheral vasculopathy warning including Raynaud's phenomenon (added 2011).
• Serotonin syndrome risk language for combinations with serotonergic drugs (added 2016).
• Updated abuse liability section following DEA scheduling reaffirmation (2019 revision).

Each revision reflects either new FAERS signals, Sentinel findings, or post-market study commitments made as part of the original NDA approval. The full labeling history is accessible at Drugs@FDA.

The EMA's EPAR for lisdexamfetamine (approved in Europe as Vyvanse and Elvanse) reflects broadly similar safety conclusions, though the European label includes additional language about potential for serotonin syndrome that the FDA incorporated slightly later.

Clinical Monitoring Recommendations Based on FAERS and Label Data

Given the signal profile above, the HealthRX medical team recommends the following monitoring schedule for patients on lisdexamfetamine, consistent with the Vyvanse label and the 2019 American Academy of Pediatrics clinical practice guideline on ADHD. AAP CPG, Pediatrics 2019.

Before Starting Treatment

Obtain a personal and family history of cardiac disease, arrhythmia, hypertension, and sudden death. Screen for personal or family psychiatric history including bipolar disorder and psychosis. Measure baseline blood pressure, pulse, weight, and height (in pediatric patients). Complete a substance use history given the Schedule II status.

At Every Follow-Up Visit

Measure blood pressure and heart rate. Ask directly about chest pain, palpitations, and shortness of breath. Screen for new psychiatric symptoms including anxiety, mood elevation, and perceptual disturbances. Reassess appetite and weight trajectory.

Annually or with Dose Changes

Repeat cardiac history review. Reassess growth parameters in pediatric patients. Review concurrent medications for serotonergic interactions. Document any new family history of cardiac events. Consider ECG if clinical history changes.

Patients reporting finger color changes in cold environments should be evaluated for peripheral vasospasm. Discontinuation of lisdexamfetamine typically resolves vasospasm within weeks, though some patients require ongoing dermatology or rheumatology involvement if Raynaud's was pre-existing.

A resting heart rate above 100 bpm on two consecutive visits despite optimization of dose timing warrants cardiology evaluation before continuing therapy.